Evidence of bisphosphonate-conjugated sitafloxacin eradication of established methicillin-resistant S. aureus infection with osseointegration in murine models of implant-associated osteomyelitis

Abstract

Eradication of MRSA osteomyelitis requires elimination of distinct biofilms. To overcome this, we developed bisphosphonate-conjugated sitafloxacin (BCS, BV600072) and hydroxybisphosphonate-conjugate sitafloxacin (HBCS, BV63072), which achieve “target-and-release” drug delivery proximal to the bone infection and have prophylactic efficacy against MRSA static biofilm in vitro and in vivo. Here we evaluated their therapeutic efficacy in a murine 1-stage exchange femoral plate model with bioluminescent MRSA (USA300LAC::lux). Osteomyelitis was confirmed by CFU on the explants and longitudinal bioluminescent imaging (BLI) after debridement and implant exchange surgery on day 7, and mice were randomized into seven groups: 1) Baseline (harvested at day 7, no treatment); 2) HPBP (bisphosphonate control for BCS) + vancomycin; 3) HPHBP (hydroxybisphosphonate control for HBCS) + vancomycin; 4) vancomycin; 5) sitafloxacin; 6) BCS + vancomycin; and 7) HBCS + vancomycin. BLI confirmed infection persisted in all groups except for mice treated with BCS or HBCS + vancomycin. Radiology revealed catastrophic femur fractures in all groups except mice treated with BCS or HBCS + vancomycin, which also displayed decreases in peri-implant bone loss, osteoclast numbers, and biofilm. To confirm this, we assessed the efficacy of vancomycin, sitafloxacin, and HBCS monotherapy in a transtibial implant model. The results showed complete lack of vancomycin efficacy while all mice treated with HBCS had evidence of infection control, and some had evidence of osseous integrated septic implants, suggestive of biofilm eradication. Taken together these studies demonstrate that HBCS adjuvant with standard of care debridement and vancomycin therapy has the potential to eradicate MRSA osteomyelitis.

References

[1] Morgenstern M et al. The AO trauma CPP bone infection registry: epidemiology and outcomes of Staphylococcus aureus bone infection. J. Orthop. Res., 2021, 39: 136-146

[2] Masters EA et al. Evolving concepts in bone infection: redefining “biofilm”, “acute vs. chronic osteomyelitis”, “the immune proteome” and “local antibiotic therapy”. Bone Res., 2019, 7: 20

[3] Masters EA et al. Skeletal infections: microbial pathogenesis, immunity and clinical management. Nat. Rev. Microbiol., 2022, 20: 385-400

[4] Moriarty TF et al. Fracture-related infection. Nat. Rev. Dis. Prim., 2022, 8: 67

[5] Varrone JJ et al. Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters. J. Orthop. Res., 2014, 32: 1389-1396

[6] Masters EA et al. Identification of penicillin binding protein 4 (PBP4) as a critical factor for Staphylococcus aureus bone invasion during osteomyelitis in mice. PLoS Pathog., 2020, 16: e1008988

[7] Schwarz EM et al. Adjuvant antibiotic-loaded bone cement: concerns with current use and research to make it work. J. Orthop. Res., 2021, 39: 227-239

[8] Sedghizadeh PP et al. Design, synthesis, and antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin conjugate for the treatment of osteomyelitis biofilms. J. Med. Chem., 2017, 60: 2326-2343

[9] Adjei-Sowah E et al. Development of bisphosphonate-conjugated antibiotics to overcome pharmacodynamic limitations of local therapy: initial results with carbamate linked sitafloxacin and tedizolid. Antibiotics, 2021, 10: 732

[10] Ren Y et al. Efficacy of bisphosphonate-conjugated sitafloxacin in a murine model of S. aureus osteomyelitis: evidence of “target & release” kinetics and killing of bacteria within Canaliculi. Front. Cell. Infect. Microbiol., 2022, 12: 910970

[11] Trombetta RP, Dunman PM, Schwarz EM, Kates SL, Awad HA. A high-throughput screening approach to repurpose FDA-approved drugs for bactericidal applications against Staphylococcus aureus small-colony variants. mSphere, 2018, 3: e00422-18

[12] Schwarz EM et al. 2018 International consensus meeting on musculoskeletal infection: research priorities from the general assembly questions. J. Orthop. Res., 2019, 37: 997-1006

[13] Metsemakers WJ et al. Antimicrobial resistance, the COVID-19 pandemic, and lessons for the orthopaedic community. J. Bone Jt. Surg. Am., 2021, 103: 4-9

[14] Yokogawa N et al. Immunotherapy synergizes with debridement and antibiotic therapy in a murine 1-stage exchange model of MRSA implant-associated osteomyelitis. J. Orthop. Res., 2018, 36: 1590-1598

[15] Buchholz HW, Elson RA, Heinert K. Antibiotic-loaded acrylic cement: current concepts. Clin. Orthop. Relat. Res., 1984, 190: 96-108

[16] Parvizi J, Gehrke T, Mont MA, Callaghan JJ. Introduction: proceedings of international consensus on orthopedic infections. J. Arthroplasty., 2019, 34: S1-S2

[17] Saeed K et al. The 2018 international consensus meeting on musculoskeletal infection: summary from the biofilm workgroup and consensus on biofilm related musculoskeletal infections. J. Orthop. Res., 2019, 37: 1007-1017

[18] Cheng AG et al. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J., 2009, 23: 3393-3404

[19] Thammavongsa V, Missiakas DM, Schneewind O. Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death. Science, 2013, 342: 863-866

[20] de Mesy Bentley KL, MacDonald A, Schwarz EM, Oh I. Chronic osteomyelitis with Staphylococcus aureus deformation in submicron canaliculi of osteocytes: a case report. JBJS Case Connect., 2018, 8: e8

[21] de Mesy Bentley KL et al. Evidence of Staphylococcus aureus deformation, proliferation, and migration in canaliculi of live cortical bone in murine models of osteomyelitis. J. Bone Min. Res., 2017, 32: 985-990

[22] Trombetta RP, de Mesy Bentley KL, Schwarz EM, Kate SL, Awad HA. A murine femoral ostectomy model with hardware exchange to assess antibiotic-impregnated spacers for implant-associated osteomyelitis. Eur. Cell Mater., 2019, 37: 431-443

[23] Sun S et al. Bisphosphonates for delivering drugs to bone. Br. J. Pharm., 2021, 178: 2008-2025

[24] Wang H et al. Synthesis of a bone-targeted bortezomib with in vivo anti-myeloma effects in mice. Pharmaceutics, 2018, 10: 154

[25] Wang H et al. Targeting bortezomib to bone increases its bone anabolic activity and reduces systemic adverse effects in mice. J. Bone Min. Res., 2020, 35: 343-356

[26] Farrell KB, Karpeisky A, Thamm DH, Zinnen S. Bisphosphonate conjugation for bone specific drug targeting. Bone Rep., 2018, 9: 47-60

[27] Xing L et al. Targeting anti-cancer agents to bone using bisphosphonates. Bone, 2020, 138: 115492

[28] Ebetino FH et al. Bisphosphonates: the role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. Bone, 2022, 156: 116289

[29] Amorena B et al. Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J. Antimicrob. Chemother., 1999, 44: 43-55

[30] Melchior MB, Fink-Gremmels J, Gaastra W. Comparative assessment of the antimicrobial susceptibility of Staphylococcus aureus isolates from bovine mastitis in biofilm versus planktonic culture. J. Vet. Med B Infect. Dis. Vet. Public Health, 2006, 53: 326-332

[31] Trombetta RP et al. Calcium phosphate spacers for the local delivery of sitafloxacin and rifampin to treat orthopedic infections: efficacy and proof of concept in a mouse model of single-stage revision of device-associated osteomyelitis. Pharmaceutics, 2019, 11: 94

[32] Nishitani K et al. Quantifying the natural history of biofilm formation in vivo during the establishment of chronic implant-associated Staphylococcus aureus osteomyelitis in mice to identify critical pathogen and host factors. J. Orthop. Res., 2015, 33: 1311-1319

[33] Lawson MA et al. Differences between bisphosphonates in binding affinities for hydroxyapatite. J. Biomed. Mater. Res B Appl. Biomater., 2010, 92: 149-155

[34] Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br. J. Clin. Pharm., 2019, 85: 1052-1062

[35] Thurlow LR et al. Staphylococcus aureus biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. J. Immunol., 2011, 186: 6585-6596

[36] Guo Y et al. In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice. Antimicrob. Agents Chemother., 2013, 57: 855-863

[37] Kourbatova EV et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am. J. Infect. Control, 2005, 33: 385-391

[38] Ishikawa M et al. Surface topography of silicon nitride affects antimicrobial and osseointegrative properties of tibial implants in a murine model. J. Biomed. Mater. Res. A, 2017, 105: 3413-3421

[39] Li D et al. Quantitative mouse model of implant-associated osteomyelitis and the kinetics of microbial growth, osteolysis, and humoral immunity. J. Orthop. Res., 2008, 26: 96-105

[40] Prabhakara R et al. Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus. Infect. Immun., 2011, 79: 5010-5018

[41] Xie C et al. Unique angiogenic and vasculogenic properties of renal cell carcinoma in a xenograft model of bone metastasis are associated with high levels of vegf-a and decreased ang-1 expression. J. Orthop. Res., 2012, 30: 325-333

[42] Li D et al. Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw. Ann. N.Y. Acad. Sci., 2010, 1192: 84-94

[43] Zhang X et al. Periosteal progenitor cell fate in segmental cortical bone graft transplantations: implications for functional tissue engineering. J. Bone Min. Res., 2005, 20: 2124-2137

[44] de Mesy Jensen KL, di Sant’Agnese PA. Large block embedding and “pop-off” technique for immunoelectron microscopy. Ultrastruct. Pathol., 1992, 16: 51-59

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(R44 AI125060)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)